Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03232671

Enrollment

180

Registered

2017-07-28

Start date

2016-03-31

Completion date

2020-09-01

Last updated

2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Diseases

Brief summary

Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.

Interventions

DIAGNOSTIC_TESTMIF ELISA

Blood sample

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All patients presenting with symptoms of heart failure to the West-German Heart and Vascular Center according to the definition of the ESC 2016. * Patients fulfilling criteria for the diagnosis of HFrEF * Patients fulfilling criteria for the diagnosis of HFpEF * Patients fulfilling criteria for the diagnosis of HFmrEF * Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.

Exclusion criteria

* Age \< 18 years * Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016 * Denial to participate

Design outcomes

Primary

Measure	Time frame
180 days mortality	180 days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026